BC Extra | May 7, 2015
Top Story

Alexion to acquire Synageva

Synageva BioPharma Corp. (NASDAQ:GEVA) soared $107.52 (112%) to $203.39 on news that Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) will acquire the company for $115 in cash and 0.6581 Alexion shares per Synageva share, or about $9 billion...
BioCentury | Jan 2, 2012
Finance

Living creatively

For small, early stage biotech companies, 2012 could be the year of living creatively. Although public biotechs raised more funds last year than ever before, the vast majority of the money was debt financing by...
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
BC Week In Review | Nov 7, 2011
Company News

Synageva, Trimeris deal

Synageva completed its merger with infectious disease company Trimeris in a stock deal. The combined company will be known as Synageva BioPharma Corp. and has begun trading on NASDAQ under the symbol "GEVA" (see BioCentury,...
BC Innovations | Sep 15, 2011
Cover Story

New targets for HIV

The mechanisms by which HIV binds to and fuses with host cells are well documented, but the pathway mediating the intermediate steps between binding and fusion is murky. Now, researchers in France and Italy have...
BC Week In Review | Jun 20, 2011
Company News

Synageva, Trimeris deal

Synageva will merge with infectious disease company Trimeris in a stock deal. Synageva stockholders will own about 75%, while Trimeris shareholders will own the remaining 25% of the newco, to be called Synageva BioPharma Corp....
BC Innovations | Jun 9, 2011
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV Tat protein In vitro studies suggest cyclic peptidomimetics that block interactions between Tat and the transactivation response...
BC Week In Review | Oct 11, 2010
Company News

Trimeris, Novartis, Roche deal

Trimeris will no longer be responsible for $18.7 million owed to Roche related to marketing expenses for Fuzeon enfuvirtide as part of an amended 1999 deal in which the companies were developing the viral fusion...
BC Innovations | Jun 3, 2010
Distillery Therapeutics

Indication: Infectious disease

Infectious disease HIV/AIDS HIV gp41 In vitro and in vivo studies identified HIV-1 gp41 mimetics that could be used to generate immune responses against the virus. The gp41 prehairpin fusion intermediate is an HIV protein...
BioCentury | Mar 1, 2010
Finance

Earnings on deck

Earnings on deck Company Date Pre/post mkt 4Q09 EPS est 4Q08 EPS Expected chg Integra LifeSciences Holdings Corp. (NASDAQ:IART) 3/1 Pre $0.58 $0.53 9% Ipsen Group (Euronext:IPN) 3/1 Pre NA €1.75 (A) NA Trimeris Inc....
Items per page:
1 - 10 of 352
BC Extra | May 7, 2015
Top Story

Alexion to acquire Synageva

Synageva BioPharma Corp. (NASDAQ:GEVA) soared $107.52 (112%) to $203.39 on news that Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) will acquire the company for $115 in cash and 0.6581 Alexion shares per Synageva share, or about $9 billion...
BioCentury | Jan 2, 2012
Finance

Living creatively

For small, early stage biotech companies, 2012 could be the year of living creatively. Although public biotechs raised more funds last year than ever before, the vast majority of the money was debt financing by...
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
BC Week In Review | Nov 7, 2011
Company News

Synageva, Trimeris deal

Synageva completed its merger with infectious disease company Trimeris in a stock deal. The combined company will be known as Synageva BioPharma Corp. and has begun trading on NASDAQ under the symbol "GEVA" (see BioCentury,...
BC Innovations | Sep 15, 2011
Cover Story

New targets for HIV

The mechanisms by which HIV binds to and fuses with host cells are well documented, but the pathway mediating the intermediate steps between binding and fusion is murky. Now, researchers in France and Italy have...
BC Week In Review | Jun 20, 2011
Company News

Synageva, Trimeris deal

Synageva will merge with infectious disease company Trimeris in a stock deal. Synageva stockholders will own about 75%, while Trimeris shareholders will own the remaining 25% of the newco, to be called Synageva BioPharma Corp....
BC Innovations | Jun 9, 2011
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV Tat protein In vitro studies suggest cyclic peptidomimetics that block interactions between Tat and the transactivation response...
BC Week In Review | Oct 11, 2010
Company News

Trimeris, Novartis, Roche deal

Trimeris will no longer be responsible for $18.7 million owed to Roche related to marketing expenses for Fuzeon enfuvirtide as part of an amended 1999 deal in which the companies were developing the viral fusion...
BC Innovations | Jun 3, 2010
Distillery Therapeutics

Indication: Infectious disease

Infectious disease HIV/AIDS HIV gp41 In vitro and in vivo studies identified HIV-1 gp41 mimetics that could be used to generate immune responses against the virus. The gp41 prehairpin fusion intermediate is an HIV protein...
BioCentury | Mar 1, 2010
Finance

Earnings on deck

Earnings on deck Company Date Pre/post mkt 4Q09 EPS est 4Q08 EPS Expected chg Integra LifeSciences Holdings Corp. (NASDAQ:IART) 3/1 Pre $0.58 $0.53 9% Ipsen Group (Euronext:IPN) 3/1 Pre NA €1.75 (A) NA Trimeris Inc....
Items per page:
1 - 10 of 352